HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional)
NIH cooperative agreements fund a HeartShare 2.0 Clinical Trial Center or up to seven Clinical Centers to coordinate and conduct precision heart failure with preserved ejection fraction clinical trial activities, deep phenotyping, recruitment, follow-up, and related specimen collection.
⚑ Separate applications are solicited for CTC and CC; same institution may need different PIs for each submission. · Foreign organizations are ineligible; foreign components within U.S. organizations are allowed. · Companion NOFO supports the Data Translation Center and is separate from this competition. · Award ceiling listed at $500,000.
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 65 good | technical depth: minor; funds applied research |
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for a new Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) for the HeartShare 2.0 program. The CTC will coordinate precision clinical trial activities focused on heart failure with preserved ejection fraction (HFpEF), including master protocol development, project management, recruitment oversight, performance milestones, and scientific conduct of trials. The CCs will recruit and retain heart failure patients and controls. The CCs will participate in all aspects of conducting a deep phenotyping protocol and longitudinal follow-up of HFpEF patients; obtaining tissue biopsies; and recruiting patients for future clinical trials.Eligible applicants may submit proposals for either the CTC or CC, but must have different PIs. Each application should include CTC or CC as part of their project title.Companion NOFO for RFA-HL-27-009 will support a Data Translation Center (DTC) for overall coordination of the HeartShare program.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Apply
View on Grants.gov → CONTACT: National Institutes of Health <nhlbiheartshare@mail.nih.gov>
Proposal brief
Proposal shell · National Institutes of Health conventions
Legacy IPPRA LLM assessment (v2.0, for comparison)
25/100 · gpt-5.4-mini · 2026-07-06
This is a biomedical clinical-trial infrastructure opportunity centered on heart failure phenotyping, patient recruitment, and longitudinal follow-up, with no explicit social science, policy, or behavioral research component. IPPRA’s survey, communication, and policy strengths are not a natural lead fit here, though there is some distant overlap with health outcomes and patient retention. Public universities are eligible, but the opportunity is aimed at clinical centers and a trial-coordination center rather than research on the human side of health systems.
Legacy scoring history
| 2026-07-06 | 25 | gpt-5.4-mini | This is a biomedical clinical-trial infrastructure opportunity centered on heart failure phenotyping, patient recruitment, and longitudinal follow-up, with no explicit social science, policy, or behavioral research component. IPPRA’s survey, communication, and policy strengths are not a natural lead fit here, though there is some distant overlap with health outcomes and patient retention. Public universities are eligible, but the opportunity is aimed at clinical centers and a trial-coordination center rather than research on the human side of health systems. |
| 2026-07-06 | 18 | gpt-5.4-mini | This is a predominantly biomedical clinical-trial opportunity focused on heart failure phenotyping, recruitment, and longitudinal follow-up, with little direct emphasis on policy, communication, or behavioral research. IPPRA’s strengths in health communication and community engagement are only tangentially relevant, and the NOFO is not a natural fit for its core portfolio. U.S. organizations are eligible, but because the opportunity is aimed at clinical centers/coordinating trial infrastructure rather than social science leadership, the relevance is limited. |